Spidy, Fen-Phen, and the Next Miracle
A neighborhood dad once nicknamed me Spidy, all arms and legs. Decades and a hundred extra pounds later, I've learned one boring truth about weight: watch what you eat, and keep moving.
Now the miracle shot is everywhere. About one in nine American adults is on a GLP-1 for weight loss. I've heard this pitch before: Rainbow Pills, Fen-Phen, Dexatrim, ephedra. Approved, celebrated, then pulled. In this episode, I look at why America got so heavy, why Japan and Vietnam didn't, what the commercials leave out about these drugs, and why the UK is reporting deaths the FDA isn't talking about.
I'm not telling anyone what to put in their body. I'm asking you to hear the whole story before you sign up for the subscription. One ask. I don't ask for donations or payments through any platform, and I have no intention of taking advertising dollars, now or in the future.The only payment I'll ever ask for is this: follow or subscribe wherever you listen. And when you hear an episode that would speak to someone you know, share it with them. If you'd like to leave a like or a comment, I'd be honored to read it.For the written word, with deeper dives, more receipts, and the same voice, find me on Substack at @kbamericanrefugeeStay awake out there.American Refugee _______________________________________________________________ SHOW NOTES
U.S. obesity
• Trust for America's Health, State of Obesity 2025 (2024 CDC data): West Virginia 41.4%, Mississippi 40.4%; Colorado 25.0%, D.C. 25.5%. 19 states at or above 35%. tfah.org/report-details/state-of-obesity-report-2025/
• CDC 2024 Adult Obesity Prevalence Maps: Midwest 35.9%, South 34.5%. cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html
• CDC NHANES 2021 to 2023: 40.3% of U.S. adults with obesity.
Global comparison
• WHO and NCD-RisC estimates via World Obesity Federation: U.S. about 42%, Mexico 36%, U.K. 27%, Germany 20%, France 11%, Switzerland 14%, Japan 4 to 6%, South Korea 6 to 7%, Vietnam about 2%.
GLP-1s
• Gallup National Health and Well-Being Index (July 2026): 11% of U.S. adults on a GLP-1 for weight loss, up from 3% in 2024.
• STEP 1 trial extension (Wilding et al., 2022): about two-thirds of lost weight regained within a year of stopping semaglutide.
• UK MHRA Yellow Card data (Aug 2026): 216 death reports (Mounjaro 120, semaglutide 59, Saxenda 37). These are suspected reactions, not confirmed causes.
• MHRA pancreatitis warning (Jan 2026).
• FDA, "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." fda.gov
Drug ads
• Only the U.S. and New Zealand allow direct-to-consumer prescription drug ads; $10.8 billion spent in 2024 (MediaRadar, via Bloomberg Law).
Weight-loss drug history
• Rainbow diet pills: American Journal of Public Health (2012); 1968 Senate hearings.
• Fen-Phen: Mayo Clinic report (NEJM, Aug 1997); FDA withdrawal request Sept 15, 1997; PBS Frontline.
• PPA (2000), ephedra (2004), sibutramine (2010), lorcaserin (2020).
• Red Dye No. 3: FDA revoked food authorization in January 2025.
Music: "Awaken Child" by Alex Kaplan. Listen and follow him wherever you stream music.